Tradestie Institutional Equity Comparison Engine

BMRN vs FDMT โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

BMRN Overall Edge

BMRN Captures Institutional Edge (2โ€“2 Pillars ยท 8โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to BioMarin Pharmaceuticals Inc (BMRN) driven by superior Valuation, Growth & Margin while FDMT counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, BMRN trades at 9.1x Forward P/E with 16.3% operating margin (+32.0% YoY revenue) versus FDMT at N/M Forward P/E and -222.7% operating margin (+4505.6% YoY). In options structure, BMRN sits in CONSOLIDATION (17th %ile IV; Dealer Gamma Walls on Pro) against FDMT sits in BREAKDOWN (10th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner BMRN
BMRN 9.1x vs FDMT N/M Fwd P/E
Growth & Margin Winner BMRN
Op Margin 16.3% vs -222.7% ยท YoY +32.0% vs +4505.6%
Momentum & Technical Winner FDMT
1Y +7.6% vs +13.3% ยท 52W Pos 42% vs 47%
Options & Structure Winner FDMT
CONSOLIDATION (17th %ile IV) vs BREAKDOWN (10th %ile IV)
BMRN NASDAQ
BioMarin Pharmaceuticals Inc
Pharmaceutical Preparations
$58.32
+1.9% 1D
Market Cap $11.0B
1M Return +6.66%
1Y Return +7.56%
Forward P/E 9.1x
Unified AI Score
52.6 / 100 HOLD
Tech 57.0 Fund 61.0 Flow 66.0 Mom 60.0
FDMT NASDAQ
4D Molecular Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$11.65
-4.74% 1D
Market Cap $669.3M
1M Return -4.04%
1Y Return +13.33%
Forward P/E N/M
Unified AI Score
51.3 / 100 HOLD
Tech 51.0 Fund 47.0 Flow 66.0 Mom 54.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: BMRN +7.56% FDMT +13.33% Spread: +5.77 pp (FDMT Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period BMRN Revenue FDMT Revenue BMRN Op. Margin FDMT Op. Margin Margin Edge
FY2018 $1.49B N/A -8.3% N/A BMRN
FY2019 $1.70B $10M -5.9% -729.4% BMRN
FY2020 $1.86B $10M -2.3% -424.0% BMRN
FY2021 $1.85B $20M -4.5% -395.5% BMRN
FY2022 $2.10B $0M 7.7% -3516.5% BMRN
FY2023 $2.42B $20M 7.7% -544.6% BMRN
FY2024 $2.85B $0M 17.0% -507678.4% BMRN
FY2025 $3.22B $90M 12.7% -187.2% BMRN

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: BMRN (8) vs FDMT (2)
Institutional Metric BMRN FDMT Criterion Row Winner
Market Capitalization Scale $11.0B $669.3M Larger Scale BMRN
Trailing P/E Ratio Valuation 8.8x N/M Lower Multiple BMRN
Forward P/E Ratio Valuation 9.1x N/M Lower Multiple BMRN
Revenue Growth (YoY) Growth +32.0% +4505.6% Higher Growth FDMT
Operating Margin (TTM) Profitability 16.3% -222.7% Higher Margin BMRN
Net Profit Margin Profitability -0.5% -208.6% Higher Margin BMRN
Return on Equity (ROE) Capital Efficiency -0.3% -56.7% Higher ROE BMRN
52-Week Range Position Momentum 42% ($49โ€“$71) 47% ($7โ€“$17) Stronger Trend FDMT
Beta / 30D Volatility Risk Regime 0.28ฮฒ ยท 31% Vol 1.89ฮฒ ยท 90% Vol Lower Realized Risk BMRN
Unified Institutional Score Composite Signal 52.6 / 100 (HOLD) 51.3 / 100 (HOLD) Higher Composite BMRN

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full BMRN vs FDMT Buy Guide
BMRN CONSOLIDATION
67d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 17th %ile
IV Regime Compressed (<25th %ile)
Live BMRN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
FDMT BREAKDOWN
62d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 10th %ile
IV Regime Compressed (<25th %ile)
Live FDMT Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither BMRN nor FDMT registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.